search for


Original Article
Clinical Courses and Outcome of Newly Diagnosed Immune Thrombocytopenia in Infants
Clin Pediatr Hematol Oncol 2018;25:97-101.
Published online October 31, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Nu Ri Hwang, M.D.1 and Kyung Duk Park, M.D.1,2

1Chonbuk National University Children's Hospital,
2Research Institute of Clinical Medicine of Chonbuk National University, Jeonju, Korea
Correspondence to: Kyung Duk Park
Department of Pediatrics, Chonbuk National University Children's Hospital, 20 Geonji-ro, Deokjin-gu, Jeonju 54907, Korea
Tel: +82-63-250-1472
Fax: +82-63-250-1464
Received September 1, 2018; Revised September 19, 2018; Accepted September 29, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Infants with immune thrombocytopenia (ITP) are at increased risk of high risk bleeding and vaccination-associated ITP. Infants with ITP respond favorably to treatment and are less likely to develop chronic ITP compared to older children. However the characteristics of this entity in infants have rarely been analyzed. We investigated the clinical characteristics and response to treatment of newly diagnosed ITP in infants under 1 year of age.
Methods: We retrospectively reviewed the medical records of newly diagnosed ITP infants between 1 month to 11 months of age at Chonbuk National University Hospital from 2002 to 2017. The demographics, complete blood count, absolute lymphocyte count (ALC), absolute neutrophil count, vaccination history, upper respiratory infection, viral study (cytomegalovirus) and treatment of patients with ITP were reviewed.
Results: A total of 85 patients satisfied the criteria for newly diagnosed ITP. Of these patients, 83 were in complete remission, 6 were in persistent remission, and 2 progressed to chronic ITP. As a result of the study, 57 patients (67%) were male. 71 patients (83.5%) were secondary ITP. Among secondary ITP, vaccination related ITP was the most common cause with 60 patients (84.5%). The mean at diagnosis was 4.3±3.2 month. There was no statistically significant difference in ALC between the time of diagnosis and treatment. Hemoglobin was 10.8 g/dL at diagnosis and increased significantly to 12.3 g/dL after treatment.
Conclusion: Ninety-seven percent of ITP patients diagnosed under 1 year of age were in remission.
Keywords: Infants, Immune thrombocytopenia, Clinical course

October 2018, 25 (2)
Full Text PDF
Send to a friend

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Kyung Duk Park 

Funding Information